Sales Force Bubble May Soon Burst; Slowing R&D Is Cause, Takeda Says
Executive Summary
Industry has reached a peak in terms of sales force expansion after years of annual increases, Takeda VP-Sales Dean Hart said Nov. 19 at a conference sponsored by The Economist in Philadelphia
You may also be interested in...
Pfizer’s New Benchmark For New Era: 8% Annual Growth Is Sustainable
The pharmaceutical industry is entering a period where average annual growth rates are likely to hover at about 8%, Pfizer CEO Hank McKinnell predicted during a Nov. 30 analyst meeting in Groton, Conn
Pfizer’s New Benchmark For New Era: 8% Annual Growth Is Sustainable
The pharmaceutical industry is entering a period where average annual growth rates are likely to hover at about 8%, Pfizer CEO Hank McKinnell predicted during a Nov. 30 analyst meeting in Groton, Conn
Pfizer Recognizes “Dark Side” Of Scale In R&D; No Sales Force Cuts Planned
Pfizer relies on competition among research teams to help ensure that its vast R&D resources do not diminish the entrepreneurial spirit within the organization, CFO David Shedlarz told the Merrill Lynch pharmaceutical and biotechnology conference Feb. 5 in New York City